Targeted Therapy

Next-generation molecular therapies designed to selectively inhibit oncogenic driver mutations (EGFR, ALK, ROS1, HER2, BRAF, BRCA) while sparing healthy normal cells.

Targeted therapy delivers molecular precision by interfering with specific proteins and signaling pathways essential for cancer growth, angiogenesis, and metastatic dissemination.

Key Modalities & Biomarkers:

  • Small Molecule Tyrosine Kinase Inhibitors (TKIs): Oral targeted agents for EGFR, ALK, ROS1, BRAF V600E, RET, and MET alterations.
  • Monoclonal Antibodies & ADCs: Anti-HER2 therapeutics (Trastuzumab, Pertuzumab) and antibody-drug conjugates (T-DM1, T-DXd).
  • PARP Inhibitors: Synthetic lethality protocols for homologous recombination deficient (BRCA1/2 mutated) malignancies.
  • CDK4/6 Inhibitors: Targeted endocrine combinations (Palbociclib, Ribociclib, Abemaciclib) for hormone receptor-positive metastatic breast cancer.
  • Serial Liquid Biopsies: Circulating tumor DNA (ctDNA) tracking to detect emerging resistance mechanisms early.
Dr. Chinmayee Agrawal

Consultation with Dr. Chinmayee Agrawal

ECMO Certified Medical Oncologist • Sarvodaya Hospital (Greater Noida West) • Sri Balaji Hospital (Ludhiana)